Does Moderna Need to Start Making Money?
2026-06-09 07:31:00 ET
Moderna (NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.
However, a lot has changed in the past few years. Although Moderna's COVID-19 vaccines remain its primary revenue stream, sales are just a fraction of what they were during the pandemic. Plus, the company is losing money hand over fist, posting a $2.8 billion net loss in 2025 and expecting billions in losses in 2026 as well.
Based on this, you might think Moderna would be a terrible investment. But I'm not sure that's the case, and there are three main reasons why.
NASDAQ: MRNA
MRNA Trading
-2.6% G/L:
$66.61 Last:
4,867,454 Volume:
$66.33 Open:
MRNA Latest News
